Biography
Michael Campbell, Ph.D. received his doctoral degree in Cancer Biology from Stanford University where he remained as a postdoctoral fellow in Oncology. Dr. Campbell was appointed Assistant Professor of Surgery at Stanford University in 1992. He joined the UCSF faculty as Assistant Professor of Surgery in 1997.
Dr. Campbell's areas of interest in research include breast neoplasms, cancer vaccines, immunotherapy, immunologic adjuvants, immunologic and biological factors, gene therapy, immunology, and breast cancer.
Education
Education
- 1978-82, University of Puget Sound, B.S., Biology
- 1978-82, University of Puget Sound, B.S., Mathematics
- 1983-87, Stanford University, Ph.D., Cancer Biology
Fellowships
- 1987-89, Stanford University, Postdoctoral Fellow, Oncology
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 54
- Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.| | View in PubMed
- Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.| | View in PubMed
- Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.| | View in PubMed
- Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.| | View in PubMed
- Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.| | View in PubMed
- Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.| | View in PubMed
- Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.| | View in PubMed
- Germline genetic contribution to the immune landscape of cancer.| | View in PubMed
- Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?| | View in PubMed
- Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.| | View in PubMed
- Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.| | View in PubMed
- The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.| | View in PubMed
- Biology of breast cancer in Nigerian women: a pilot study.| | View in PubMed
- Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.| | View in PubMed
- Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.| | View in PubMed
- Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.| | View in PubMed
- Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.| | View in PubMed
- Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.| | View in PubMed
- Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.| | View in PubMed
- Breast cancer growth prevention by statins.| | View in PubMed
- Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.| | View in PubMed
- A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.| | View in PubMed
- Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.| | View in PubMed
- Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.| | View in PubMed
- In vitro anticancer activity of twelve Chinese medicinal herbs.| | View in PubMed
- Immune dysfunction and micrometastases in women with breast cancer.| | View in PubMed
- Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells.| | View in PubMed
- Reduction of MTT by aqueous herbal extracts in the absence of cells.| | View in PubMed
- Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.| | View in PubMed
- Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.| | View in PubMed
- Ductal growth is impeded in mammary glands of C-neu transgenic mice.| | View in PubMed
- Biological therapies for breast carcinoma: concepts for improvement in survival.| | View in PubMed
- Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.| | View in PubMed
- Clinical trials of idiotype-specific vaccine in B-cell lymphomas.| | View in PubMed
- Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.| | View in PubMed
- Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.| | View in PubMed
- Interleukin 3 is a growth factor for human follicular B cell lymphoma.| | View in PubMed
- Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.| | View in PubMed
- Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy.| | View in PubMed
- Ig VH gene expression among human follicular lymphomas.| | View in PubMed
- Follicular lymphoma: a model of lymphoid tumor progression in man.| | View in PubMed
- Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.| | View in PubMed
- Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.| | View in PubMed
- Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.| | View in PubMed
- Idiotypic variation in a human B lymphoma cell line.| | View in PubMed
- Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line.| | View in PubMed
- Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.| | View in PubMed
- Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.| | View in PubMed
- Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.| | View in PubMed
- Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.| | View in PubMed
- Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.| | View in PubMed
- Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses.| | View in PubMed
- Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies.| | View in PubMed
- Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.| | View in PubMed